title: Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
abstract: OBJECTIVE
  An increased risk of drug-related liver injury has been repeatedly reported in individuals infected with hepatitis C virus (HCV) receiving the antiretroviral drug nevirapine. This study was undertaken to assess the differences in the pharmacokinetics of nevirapine between patients with HIV/HCV coinfection and HIV infection that could explain higher rates of hepatotoxicity.
  
  
  METHODS
  A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected. Advanced liver disease was an exclusion criterion in order to assess the impact of chronic HCV infection alone.
  
  
  RESULTS
  Comparing the two groups, no difference was observed between minimum and maximum drug levels or total drug exposure in terms of area under the curve.
  
  
  CONCLUSIONS
  Hepatitis C coinfection does not alter the pharmacokinetics of nevirapine in patients with preserved liver function.
authors.affiliation: Department of Internal Medicine I, Bonn University, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Vogel
authors.forename: Norbert
authors.initials: N
authors.lastname: Bertram
authors.forename: Jan-Christian
authors.initials: JC
authors.lastname: Wasmuth
authors.forename: Christoph
authors.initials: C
authors.lastname: Wyen
authors.forename: Esther
authors.initials: E
authors.lastname: Voigt
authors.forename: Carolynne
authors.initials: C
authors.lastname: Schwarze-Zander
authors.forename: Thomas
authors.initials: T
authors.lastname: Sudhop
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Jürgen K
authors.initials: JK
authors.lastname: Rockstroh
authors.forename: Christoph
authors.initials: C
authors.lastname: Reichel
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D044967:Serum / Q000737:chemistry
chemical_list: D000998:Antiviral Agents; D019829:Nevirapine